FDA Dispute Resolution Panel To Review CardioGenesis PMR Data In August
This article was originally published in The Gray Sheet
Executive Summary
CardioGenesis will rely on data previously reviewed by FDA in seeking to overturn an initial "not approvable" determination by the agency for its PMR percutaneous myocardial revascularization system